Pranoprofen | CAS#52549-17-4

MedKoo Cat#: 527789 | Name: Pranoprofen

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pranoprofen is a non-steroidal anti-inflammatory drug used in ophthalmology.

Chemical Structure

Pranoprofen

CAS#52549-17-4

Theoretical Analysis

MedKoo Cat#: 527789

Name: Pranoprofen

CAS#: 52549-17-4

Chemical Formula: C15H13NO3

Exact Mass: 255.0895

Molecular Weight: 255.27

Elemental Analysis: C, 70.58; H, 5.13; N, 5.49; O, 18.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Pranoprofen

IUPAC/Chemical Name

2-(5H-Chromeno[2,3-b]pyridin-7-yl)propanoic acid

InChi Key

TVQZAMVBTVNYLA-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)

SMILES Code

CC(C1=CC(CC2=CC=CN=C2O3)=C3C=C1)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 255.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shimada H, Kobayashi Y, Tanahashi S, Kawase A, Ogiso T, Iwaki M. Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs. Eur J Pharm Sci. 2018 Jan 15;112:132-138. doi: 10.1016/j.ejps.2017.11.018. Epub 2017 Nov 22. PubMed PMID: 29174986. 2: Song Y, Ding Y, Jia Y, Zhao J, Gao K, Lu C, Li R, Wen A. Bioequivalence and food effect study of two zaltoprofen preparations in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2017 Dec;55(12):923-930. doi: 10.5414/CP203047. PubMed PMID: 29092729. 3: Jian-Wei L, Xiu-Yun L, Ai-Jun D. Effectiveness of heparin eye drops in paraquat-induced ocular injury. Cutan Ocul Toxicol. 2017 Dec;36(4):377-380. doi: 10.1080/15569527.2017.1303706. Epub 2017 Mar 27. PubMed PMID: 28279080. 4: Liu C, Quan P, Li S, Zhao Y, Fang L. A systemic evaluation of drug in acrylic pressure sensitive adhesive patch in vitro and in vivo: The roles of intermolecular interaction and adhesive mobility variation in drug controlled release. J Control Release. 2017 Apr 28;252:83-94. doi: 10.1016/j.jconrel.2017.03.003. Epub 2017 Mar 6. PubMed PMID: 28274741. 5: Cañadas C, Alvarado H, Calpena AC, Silva AM, Souto EB, García ML, Abrego G. In vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration. Int J Pharm. 2016 Sep 25;511(2):719-27. doi: 10.1016/j.ijpharm.2016.07.055. Epub 2016 Jul 30. PubMed PMID: 27480398. 6: Cui H, Quan P, Zhou Z, Fang L. Development of a drug-in-adhesive patch combining ion pair and chemical enhancer strategy for transdermal delivery of zaltoprofen: pharmacokinetic, pharmacodynamic and in vitro/in vivo correlation evaluation. Drug Deliv. 2016 Nov;23(9):3461-3470. Epub 2016 Jul 16. PubMed PMID: 27257038. 7: Abrego G, Alvarado H, Souto EB, Guevara B, Bellowa LH, Garduño ML, Garcia ML, Calpena AC. Biopharmaceutical profile of hydrogels containing pranoprofen-loaded PLGA nanoparticles for skin administration: In vitro, ex vivo and in vivo characterization. Int J Pharm. 2016 Mar 30;501(1-2):350-61. doi: 10.1016/j.ijpharm.2016.01.071. Epub 2016 Feb 1. PubMed PMID: 26844786. 8: Kwon YH, An SH. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy: author's response. Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1431-2. doi: 10.1007/s00417-016-3278-1. Epub 2016 Jan 21. PubMed PMID: 26794221. 9: Kaya A, Aksoy Y, Sevinç MK, Diner O. Comment on: "Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy". Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1429. doi: 10.1007/s00417-016-3277-2. Epub 2016 Jan 21. PubMed PMID: 26794219. 10: Mishra R, Prabhavalkar KS, Bhatt LK. Preparation, optimization, and evaluation of Zaltoprofen-loaded microemulsion and microemulsion-based gel for transdermal delivery. J Liposome Res. 2016 Dec;26(4):297-306. doi: 10.3109/08982104.2015.1120746. Epub 2016 Jan 19. PubMed PMID: 26785055. 11: Lee JS, Kim YH, Park YM. The Toxicity of Nonsteroidal Anti-inflammatory Eye Drops against Human Corneal Epithelial Cells in Vitro. J Korean Med Sci. 2015 Dec;30(12):1856-64. doi: 10.3346/jkms.2015.30.12.1856. Epub 2015 Nov 30. PubMed PMID: 26713063; PubMed Central PMCID: PMC4689832. 12: An SH, Kwon YH. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016 Aug;254(8):1489-96. doi: 10.1007/s00417-015-3215-8. Epub 2015 Nov 9. PubMed PMID: 26553195. 13: Cui H, Quan P, Zhao H, Wen X, Song W, Xiao Y, Zhao Y, Fang L. Mechanism of Ion-Pair Strategy in Modulating Skin Permeability of Zaltoprofen: Insight from Molecular-Level Resolution Based on Molecular Modeling and Confocal Laser Scanning Microscopy. J Pharm Sci. 2015 Oct;104(10):3395-403. doi: 10.1002/jps.24543. Epub 2015 Jun 17. PubMed PMID: 26349639. 14: Jia L, Hu C, Wang H, Liu Y, Liu X, Zhang YY, Li W, Wang LX, Cao YF, Fang ZZ. Chirality Influence of Zaltoprofen Towards UDP-Glucuronosyltransferases (UGTs) Inhibition Potential. Chirality. 2015 Jun;27(6):359-63. doi: 10.1002/chir.22436. Epub 2015 Apr 22. PubMed PMID: 25903196. 15: Luo A, Wan Q, Fan H, Chen Z, Wu X, Huang X, Zang L. [[Chiral separation of five arylpropionic acid drugs and determination of their enantiomers in pharmaceutical preparations by reversed-phase high performance liquid chromatography with cellulose-tris-(4-methylbenzoate) stationary phase]]. Se Pu. 2014 Sep;32(9):1013-8. Chinese. PubMed PMID: 25752097. 16: Abrego G, Alvarado H, Souto EB, Guevara B, Bellowa LH, Parra A, Calpena A, Garcia ML. Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration. Eur J Pharm Biopharm. 2015 Sep;95(Pt B):261-70. doi: 10.1016/j.ejpb.2015.01.026. Epub 2015 Feb 11. PubMed PMID: 25681744. 17: Iwatsuka K, Inada K, Ueoka H, Otsuka T, Maeda M, Yamaguchi M, Yasueda S. Effect of textured eye drop bottles on the photostability of pranoprofen 0.1% ophthalmic solution. Drug Dev Ind Pharm. 2015;41(9):1526-31. doi: 10.3109/03639045.2014.971028. Epub 2015 Jul 21. PubMed PMID: 25308744. 18: Liu C, Liu Y, Ye S, Liu L, Zhang W, Wu M. Effect of topical nonsteroidal anti-inflammatory drugs and nuclear hardness on maintenance of mydriasis during phacoemulsification surgery. J Ocul Pharmacol Ther. 2014 Dec;30(10):831-6. doi: 10.1089/jop.2013.0244. PubMed PMID: 25230350. 19: Abrego G, Alvarado HL, Egea MA, Gonzalez-Mira E, Calpena AC, Garcia ML. Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen. J Pharm Sci. 2014 Oct;103(10):3153-64. doi: 10.1002/jps.24101. Epub 2014 Aug 4. PubMed PMID: 25091511. 20: Chen J, Dong F, Chen W, Sun X, Deng Y, Hong J, Zhang M, Yang W, Liu Z, Xie L. Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial. Chin Med J (Engl). 2014;127(13):2407-12. PubMed PMID: 24985574.